7月2日,华润双鹤(600062)发布公告,公司全资子公司华润紫竹药业有限公司收到国家药监局颁发的J002药物临床试验批准通知书。经审查,2025年4月16日受理的J002临床试验申请符合药品注册的有关要求,同意开展临床试验。J002适用于干眼的治疗,由华润紫竹和温州医科大学联合开发,截至本公告日,公司针对该药品累计研发投入1557万元。2025年一季度,华润双鹤实现收入30.79亿元,归母净利润...
Source Link7月2日,华润双鹤(600062)发布公告,公司全资子公司华润紫竹药业有限公司收到国家药监局颁发的J002药物临床试验批准通知书。经审查,2025年4月16日受理的J002临床试验申请符合药品注册的有关要求,同意开展临床试验。J002适用于干眼的治疗,由华润紫竹和温州医科大学联合开发,截至本公告日,公司针对该药品累计研发投入1557万元。2025年一季度,华润双鹤实现收入30.79亿元,归母净利润...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.